Avapritinib

(Ayvakit)

Avapritinib

Drug updated on 11/14/2023

Dosage FormTablet (oral: 100 mg, 200 mg, 300 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
  • For the treatment of adult patients with advanced systematic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL).

Product Monograph / Prescribing Information

Document TitleYearSource
Ayvakit (avapritinib) Prescribing Information.2021Blueprint Medicines Corporation, Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines